File name .JPG
File alt. text
Image should be px wide x px tall.
Select Image
home - Pancreas - Pancreatic Cancers - Somatostatinoma Written by Dr Sebastian Zeki

Knows the presentation investigation and staging of pancreatic

Recognises the importance of considering and being able to identify
uncommon pancreatic tumours (such as neuroendocrine or
intrapapillary mucinous tuours)

Knows the range of potential therapies and recognises the factors
that make such tumours potentially operable or inoperable

Knows the prevalence and natural history of benign cysts/serous
cystadenoma and potentially malignant cystic lesions

Knows the options for palliative treatment
Shows ability to sequence investigations appropriately
Understands value of multi-disciplinary team
Recognises the importance of considering possibility that the tumour
is unusual

Communicates effectively within the multi-disciplinary team and with
the patient and their family


D cells D cells Somatostatinoma Pancreatic Somato-statinoma2/3rds in head Duodenal somatostatinomausually ampullary/ periampullaryGet psamomma bodiesAssociated with Von Recklinghausen’s disease; can rarely occur elsewhereRarely associated with Somato-statinoma syndrome EpidemiologyThe incidence is the same in both sexes.The average age of diagnosis is 50.Only 10% get the syndrome.75% have metastasised by presentation. Can rarely occur elsewhere (eg colon) Somatostatinoma Syndrome Features:Diabetes mellitus (from inhibited insulin).Cholelithiasis (from inhibited CCK).Diarrhoea with steatorrhea ( from inhibited pancreatic enzyme and bicarb secretion). DiagnosisThe somatostatin level >160 pg/mL.US/CT/MRI ca visulaise the lesion. Prognosis5-year survival rates are 15 %.Outcomes are better in patients with duodenal somatostatinomas. D cells Written by Dr Sebastian Zeki

Related Stories

PARP inhibitor era in ovarian cancer treatment: a systematic review and meta-analysis of randomized controlled trials

Assessing visibility and bone changes of spinal metastases in CT scans: a comprehensive analysis across diverse cancer types

Application of Mid-Pancreatectomy with End-to-End Anastomosis in Pancreatic Benign Tumors

Laparoscopic Duodenum-Preserving Pancreatic Head Resection via Inferior Infracolic Approach: A Surgical Approach for Benign Lesions

Endothelial YAP/TEAD1-CXCL17 signaling recruits myeloid-derived suppressor cells against liver ischemia-reperfusion injury